Acurx Pharmaceuticals, Inc.

NasdaqCM:ACXP Stock Report

Market Cap: US$7.2m

Acurx Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:ACXP Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Jan 25BuyUS$10,000Jack DeanIndividual492.6US$20.30
06 Jan 25BuyUS$50,000Robert DeLucciaIndividual2,463.05US$20.30
06 Jan 25BuyUS$10,000James DonohueIndividual492.6US$20.30
06 Jan 25BuyUS$50,000David LuciIndividual2,463.05US$20.30
06 Jan 25BuyUS$25,000Carl SailerIndividual1,231.55US$20.30
06 Jan 25BuyUS$25,000Joseph ScodariIndividual1,231.55US$20.30

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ACXP?
Owner TypeNumber of SharesOwnership Percentage
Institutions93,3136.11%
Individual Insiders128,6058.43%
Hedge Funds144,4749.47%
General Public1,159,83576%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 87.9%.

Top Shareholders

Top 25 shareholders own 23.56% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.47%
Armistice Capital LLC
144,474US$683.4k-0.98%0.02%
3.76%
David Luci
57,377US$271.4k0%no data
3.32%
Robert DeLuccia
50,702US$239.8k0%no data
0.98%
3i Fund
14,964US$70.8k0%0.45%
0.97%
Prospect Financial Services LLC
14,838US$70.2k-19%0.04%
0.62%
Robert Shawah
9,460US$44.7k0%no data
0.48%
Geode Capital Management, LLC
7,320US$34.6k-14.6%no data
0.48%
The Vanguard Group, Inc.
7,276US$34.4k-72.5%no data
0.47%
Carl Sailer
7,109US$33.6k0%no data
0.37%
Orca Capital GmbH
5,670US$26.8k0%0.31%
0.35%
Morgan Stanley
5,310US$25.1k0%no data
0.29%
Renaissance Technologies LLC
4,389US$20.8k230%no data
0.28%
Cambridge Investment Research Advisors, Inc.
4,250US$20.1k467%no data
0.27%
Sabby Management, LLC
4,094US$19.4k-96%0.12%
0.23%
Susquehanna International Group, LLP
3,487US$16.5k0%no data
0.2%
O'Brien Greene & Co Inc
3,000US$14.2k0%no data
0.18%
Virtu Financial, Inc.
2,756US$13.0k0%no data
0.14%
State Street Global Advisors, Inc.
2,173US$10.3k0%no data
0.13%
UBS Asset Management AG
1,937US$9.2k96,800%no data
0.12%
XTX Markets Limited
1,884US$8.9k0%no data
0.099%
Hudson Bay Capital Management LP
1,506US$7.1k0%no data
0.098%
NBC Securities, Inc.
1,500US$7.1k0%no data
0.092%
Jane Street Group, LLC
1,401US$6.6k0%no data
0.091%
Joseph Scodari
1,385US$6.6k0%no data
0.09%
Jack Dean
1,377US$6.5k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/09 02:18
End of Day Share Price 2025/11/07 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acurx Pharmaceuticals, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Antonio ArceH.C. Wainwright & Co.
Matthew KellerH.C. Wainwright & Co.